Immune DIREcted and Cancer-selective immunoTherapy

Informations projet

I-DireCT

N° de convention de subvention: 813871

DOI 10.3030/813871

Projet clôturé

Date de signature de la CE 21 Août 2018

Date de début 1 Janvier 2019

Date de fin 30 Septembre 2023

Financé au titre de

• EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions

Coût total € 2 532 975,22

Contribution de l’UE € 2 532 975,22

Coordonné par

ACADEMISCH ZIEKENHUIS GRONINGEN
Netherlands

CORDIS fournit des liens vers les livrables publics et les publications des projets HORIZON.

Les liens vers les livrables et les publications des projets du 7e PC, ainsi que les liens vers certains types de résultats spécifiques tels que les jeux de données et les logiciels, sont récupérés dynamiquement sur OpenAIRE .

Livrables

Documents, reports (11)

Frontiers in Immunology EBook
List of PhDs theses
Presentations at Antibody engineering workshops 2

Special IDireCT sessions at international conferences workshops

Presentations at Antibody engineering workshops

Special IDireCT sessions at international conferences workshops

Characterization of new tumour-selective TNFR family-targeted drugs

Characterization of new tumourselective TNFR familytargeted drugs

List of publications I-DireCT

List of publications of all IDireCT members

Update 4 online knowledge bases
Update 2 online knowledge bases
Update 1 online knowledge bases
Identification and pre-clinical validation of tumour-targeted checkpoint drugs

Identification and preclinical validation of tumourtargeted checkpoint drugs

Update 3 online knowledge bases

Other (3)

Report on kick-off meeting
Press event
I-DireCT summer school

Websites, patent fillings, videos etc. (1)

Website

I-DireCT public website

Publications

Peer reviewed articles (20)

DSP107 combines inhibition of CD47/SIRPα axis with activation of 4-1BB to trigger anticancer immunity

Auteurs: Ewa Cendrowicz; Lisa Jacob; Shirley Greenwald; Ami Tamir; Iris Pecker; Rinat Tabakman; Lucy Ghantous; Liat Tamir; Roy Kahn; Jasmine Avichzer; Alexandra Aronin; Shira Amsili; Elina Zorde-Khvalevsky; Yosi Gozlan; Martijn Vlaming; Gerwin Huls; Tom van Meerten; Michal Elhalel Dranitzki; Adam Foley-Comer; Yaron Pereg; Amnon Peled; Ayelet Chajut; Edwin Bremer
Publié dans: VOLUME=41;ISSN=0392-9078;TITLE=Journal of experimental & clinical cancer research, Numéro 5, 2022, ISSN 1756-9966
Éditeur: BioMed Central Ltd
DOI: 10.1186/s13046-022-02256-x

CD20 positive CD8 T cells are a unique and transcriptionally-distinct subset of T cells with distinct transmigration properties

Auteurs: Martijn Vlaming, Vrouyr Bilemjian, Jimena Álvarez Freile, Harm Jan Lourens, Nienke van Rooij, Gerwin Huls, Tom van Meerten, Marco de Bruyn, Edwin Bremer
Publié dans: Scientific Reports, 2021, ISSN 2045-2322
Éditeur: Nature Publishing Group
DOI: 10.1038/s41598-021-00007-0

Receptor Oligomerization and Its Relevance for Signaling by Receptors of the Tumor Necrosis Factor Receptor Superfamily

Auteurs: Kirstin Kucka, Harald Wajant
Publié dans: Frontiers in Cell and Developmental Biology, Numéro 8, 2021, ISSN 2296-634X
Éditeur: Frontiers Media S.A.
DOI: 10.3389/fcell.2020.615141

Whispering Gallery Modes-based biosensors for real-time monitoring and binding characterization of antibody-based cancer immunotherapeutics

Auteurs: Jimena Álvarez Freile; Ghizlane Choukrani; Kerstin Zimmermann; Edwin Bremer; Lars Dähne
Publié dans: Sensors and actuators b-Chemical, 346:130512. Elsevier Science, Numéro 4, 2021, ISSN 0925-4005
Éditeur: Elsevier BV
DOI: 10.1016/j.snb.2021.130512

Development of vaterite particles for therapeutic protein drug delivery and pH-sensitive release mimicking the tumor microenvironment.

Auteurs: Ghizlane Choukrani, Jimena Álvarez Freile, Wei Wan, Gabriella Egri, Natasha Ustyanovska Avtenyuk (ESR2, UMCG/SURF), Valerie Wiersma, Edwin Bremer, Lars Dähne
Publié dans: Particle, 2021, ISSN 2571-712X
Éditeur: MDPI AG
DOI: 10.1002/ppsc.202100012

Towards Immunotherapy-Induced Normalization of the Tumor Microenvironment

Auteurs: Vinicio Melo, Edwin Bremer, John D. Martin
Publié dans: Frontiers in immunology, 2022, ISSN 1664-3224
Éditeur: Frontiers Media S.A.
DOI: 10.3389/fcell.2022.908389

CD24 is a potential immunotherapeutic target for Mantle Cell Lymphoma

Auteurs: Jimena Álvarez Freile, Natasha Ustyanovska Avtenyuk, Macarena González Corrales, Harm Jan Lourens, Gerwin Huls, Tom van Meerten, Ewa Cendrowicz, and Edwin Bremer
Publié dans: Biomedicines, 2022, ISSN 2227-9059
Éditeur: MDPI
DOI: 10.3390/biomedicines10051175

Membrane lymphotoxin-α2β is a novel tumor necrosis factor (TNF) receptor 2 (TNFR2) agonist

Auteurs: Kucka, Kirstin; Lang, Isabell; Zhang, Tengyu; Siegmund, Daniela; Medler, Juliane; Wajant, Harald
Publié dans: Cell Death and Disease, Vol 12, Iss 4, Pp 1-9 (2021), Numéro 6, 2021, ISSN 2041-4889
Éditeur: Nature Publishing Group
DOI: 10.1038/s41419-021-03633-8

The Novel Immune Checkpoint GPR56 Is Expressed on Tumor-Infiltrating Lymphocytes and Selectively Upregulated upon TCR Signaling

Auteurs: Vrouyr Bilemjian; Martijn R. Vlaming; Jimena Álvarez Freile; Gerwin Huls; Marco De Bruyn; Edwin Bremer
Publié dans: Cancer (Basel), Numéro 9, 2023, ISSN 2072-6694
Éditeur: Multidisciplinary Digital Publishing Institute (MDPI)
DOI: 10.3390/cancers14133164

CD40- and 41BB-specific antibody fusion proteins with PDL1 blockade-restricted agonism

Auteurs: Juliane Medler, Kirstin Kucka, Vinicio Melo, Tengyu Zhang, Stefan von Rotenhan, Jakob Ulrich, Edwin Bremer, Michael Hudecek, Andreas Beilhack, and Harald Wajant
Publié dans: Theranostics, 2022, ISSN 1838-7640
Éditeur: Ivyspring International Publisher
DOI: 10.7150/thno.66119

Anti-Fn14 Antibody-Conjugated Nanoparticles Display Membrane TWEAK-Like Agonism.

Auteurs: Ahmed Aido; Olena Zaitseva; Harald Wajant; Matej Buzgo; Aiva Simaite
Publié dans: Pharmaceutics, Numéro 6, 2021, ISSN 1999-4923
Éditeur: Multidisciplinary Digital Publishing Institute (MDPI)
DOI: 10.3390/pharmaceutics13071072

Galectin-9 has non-apoptotic cytotoxic activity towards Acute Myeloid Leukemia independent of cytarabine resistance.

Auteurs: Ghizlane Choukrani, Nienke Visser, Natasha Ustyanovska Avtenyuk, Mirjam Olthuis, Glenn Marsman, Emanuele Ammatuna, Harm Jan Lourens, Toshiro Niki, Gerwin Huls, Edwin Bremer and Valerie R. Wiersma.
Publié dans: Cell Death Discovery, 2023, ISSN 2058-7716
Éditeur: Nature Publishing Group
DOI: 10.1038/s41420-023-01515-w

Facing the Challenges of Pharmaceutical Research Using Whispering Gallery Modes-Based Biosensors

Auteurs: Lars Dähne
Publié dans: American Journal of Biomedical Science & Research, Numéro 8/2, 2020, Page(s) 161-162, ISSN 2642-1747
Éditeur: Biomedgrid
DOI: 10.34297/ajbsr.2020.08.001259

Galectin-9 Triggers Neutrophil-Mediated Anticancer Immunity

Auteurs: Natasha Ustyanovska Avtenyuk; Ghizlane Choukrani; Emanuele Ammatuna; Toshiro Niki; Ewa Cendrowicz; Harm Jan Lourens; Gerwin Huls; Valerie R. Wiersma; Edwin Bremer
Publié dans: Biomedicines, Vol 10, Iss 66, p 66 (2022), Numéro 4, 2021, ISSN 2227-9059
Éditeur: MDPI
DOI: 10.3390/biomedicines10010066

Antibody-based soluble and membrane-bound TWEAK mimicking agonists with FcγR-independent activity.

Auteurs: Zaitseva O, Hoffmann A, Löst M, Anany MA, Zhang T, Kucka K, Wiegering A, Otto C, Wajant H.
Publié dans: Frontiers in immunology, 2023, ISSN 1664-3224
Éditeur: Frontiers Media S.A.
DOI: 10.3389/fimmu.2023.1194610

The Neutrophil: The Underdog That Packs a Punch in the Fight against Cancer

Auteurs: Natasha Ustyanovska Avtenyuk, Nienke Visser, Edwin Bremer, Valerie R. Wiersma
Publié dans: International Journal of Molecular Sciences, Numéro 21/21, 2020, Page(s) 7820, ISSN 1422-0067
Éditeur: Multidisciplinary Digital Publishing Institute (MDPI)
DOI: 10.3390/ijms21217820

Tumor infiltrating CD8/CD103/TIM-3-expressing lymphocytes in epithelial ovarian cancer co-express CXCL13 and associate with improved survival

Auteurs: Martijn Vlaming, Vrouyr Bilemjian, Jimena Álvarez Freile, Vinicio Melo, Annechien Plat, Gerwin Huls, Hans W. Nijman, Marco de Bruyn, Edwin Bremer
Publié dans: Front. Immunol., 2022, ISSN 1664-3224
Éditeur: Frontiers Media S.A
DOI: 10.3389/fimmu.2022.1031746

Using Nanomedicine to Drive Advances in Cancer Immunotherapy: A Mini Review.

Auteurs: Choukrani G, Freile JA, Bremer E, Daehne L
Publié dans: American Journal of Biomedical Science & Research, 2020, ISSN 2642-1747
Éditeur: Biomedgrid
DOI: 10.34297/ajbsr.2020.08.001248

EGFR-selective activation of CD27 co-stimulatory signaling by a bispecific antibody enhances anti-tumor activity of T cells

Auteurs: Vinicio Melo, Levi Collin Nelemans, Martijn Vlaming, Harm Jan Lourens, Valerie R. Wiersma, Vrouyr Bilemjian, Gerwin Huls, Marco de Bruyn, and Edwin Bremer
Publié dans: Frontiers in immunology, 2023, ISSN 1664-3224
Éditeur: Frontiers Media S.A.
DOI: 10.3389/fimmu.2023.1191866

A luminescence-based method to assess antigen presentation and antigen-specific T cell responses for in vitro screening of immunomodulatory checkpoints and therapeutics

Auteurs: Jimena Álvarez Freile; Yuzhu Qi; Lisa Jacob; Maria Franceskin Lobo; Harm Jan Lourens; Gerwin Huls; Edwin Bremer
Publié dans: Crossref, Numéro 2, 2023, ISSN 1664-3224
Éditeur: Frontiers Media S.A
DOI: 10.3389/fimmu.2023.1233113

Thesis and dissertations (1)

Advancing Cancer Immunotherapy with Nanomedicine

Auteurs: Ghizlane Choukrani
Publié dans: 2023
Éditeur: University of Groningen
DOI: 10.33612/diss.660794643